Emory University

Fob Synthesis, Inc.

Merck + Co., Inc.

Yale University

Woo-Baeg Choi

Dennis C Liotta

Raymond F Schinazi

Ralph P Volante

Paul J Reider

Joseph E Lynch

Deog-Il Kim

Hyung-Yeul Joo

Ewa Kowalik

Andrew S Thompson

Ichiro Shinkai

Guy R Humphrey

Shuli Mao

Ewa Gruszecka-Kowalik

Shuangpei Liu

Yongfeng Li

Hywyn R Churchill

Yung-Chi Cheng

Michel M Chartrain

Ioannis N Houpis

Audrey Molina

David Menaldino

Jaemoon Lee

Shigeko Yamazaki

Takashi Tomioka

Martin Bouygues

Michael W Hager

Phong Truong

Brian Min

Hywyn Ro Churchill

The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

Carbapenem compounds and compositions for the treatment of bacterial infections

The present invention provides &#x3b2;-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

Carbapenem antibacterials with gram-negative activity

The present invention provides &#x3b2;-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of &#x3b2;-methyl carbapenems which are useful as antibacterial agents.

Carbapenem antibacterials with gram-negative activity and processes for their preparation

The present invention provides &#x3b2;-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions, wherein the compounds are generally of the Formulae The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

The present invention provides &#x3b2;-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions, wherein the compounds are generally of the Formulae  The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of &#xff;-methyl carbapenems which are useful as antibacterial agents.

Gram-positive carbapenem antibacterials and processes for their preparation

A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (&#x2212;)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.

Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers

A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5' or Nalkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A process for the resolution of a racemic mixture of nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.

Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane

A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (&minus;)-2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.

Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers

Intermediates in the synthesis of 1,3-Oxathiolane Nucleosides.

Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers

A process for making a beta methyl carbapenem intermediate is disclosed. A compound of formula I:

Preparation of betamethyl carbapenem intermediates

The present invention relates to a method of preparing BCH-189 and various analogs of BCH-189 from inexpensive precursors with the option of introducing functionality as needed. This synthetic route allows the stereoselective preparation of the biologically active isomer of these compounds, .beta.-BCH-189 and related compounds. Furthermore, the steochemistry at the nucleoside 4' position can be controlled to produce enantiomerically-enriched .beta.-BCH-189 and its analogs.

Method and compositions for the synthesis of BCH-189 and related

Growing community of inventors

North Brunswick, NJ, United States of America

Woo-Baeg Choi